Objective: Anti-cyclic citrullinated peptide (anti-CCP) antibodies are highly specific markers for rheumatoid arthritis (RA) and useful for predicting RA development and progression. However, it has not been fully determined whether anti-CCP antibodies are associated with pulmonary diseases in RA patients. In the present study, we aimed to elucidate the relationships between anti-CCP antibodies and pulmonary diseases, particularly interstitial lung disease (ILD) and bronchiolitis.
Design And Methods: Using an enzyme-linked immunosorbent assay, the presence of serum anti-CCP antibodies was examined in 18 RA patients with ILD and bronchiolitis who were diagnosed based on pathologic findings. A further 36 RA subjects without any pulmonary diseases served as a reference population.
Results: No significant differences were found for the prevalences and levels of anti-CCP antibodies between patients with and without ILD and follicular bronchiolitis.
Conclusion: Detection of serum anti-CCP antibodies has no association with pulmonary diseases in RA patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinbiochem.2008.06.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objectives: We aimed to assess the anti-mutated citrullinated vimentin (anti-MCV) antibodies in RA patients' serum and to explore their association with interstitial lung disease (ILD).
Methods: Eighty rheumatoid arthritis (RA) patients and forty healthy controls were included in this case-control study. Of these patients, forty had ILD, and forty without ILD.
Obesity and fibromyalgia are associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA) independent of age and gender.
Arthritis Res Ther
January 2025
Department of Biomedical Sciences, Humanitas University, Via R Levi Montalcini 4, Pieve Emanuele, Milan, 20090, Italy.
Background: There is still a significant proportion of patients with rheumatoid arthritis (RA) in whom multiple therapeutic lines are ineffective. These cases are defined by the EULAR criteria as Difficult-to-Treat RA (D2T-RA) for which there is limited knowledge of predisposing factors.
Objective: To identify the clinical features associated with D2T-RA in real-life practice.
Large-scale multicenter study reveals anticitrullinated SR-A peptide antibody as a biomarker and exacerbator for rheumatoid arthritis.
Sci Adv
January 2025
Department of Rheumatology and Immunology, Peking University People's Hospital & Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
Current diagnosis and treatment of rheumatoid arthritis (RA) is still challenging. More than one-third of patients with RA could not be accurately diagnosed because of lacking biomarkers. Our recent study reported that scavenger receptor-A (SR-A) is a biomarker for RA, especially for anticyclic citrullinated peptide antibody (anti-CCP)-negative RA.
View Article and Find Full Text PDFEvaluation of hematological markers as prognostic tools in rheumatoid arthritis.
BMC Rheumatol
December 2024
Molecular Medicine Research Center, Khomein University of Medical Sciences, Khomein, Iran.
Background: Reducing inflammation is central to the management of RA. However, commonly used markers such as CRP and ESR, along with the DAS-28 score, have shown limitations. Hematologic indices, such as platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), and neutrophil-lymphocyte ratio (NLR), show potential as reliable indicators of inflammation in RA.
View Article and Find Full Text PDFPreclinical RA: How to halt its progression.
Best Pract Res Clin Rheumatol
December 2024
Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 97239, USA; Rheumatology Section, VA Portland Health Care System, Portland, OR, 97239, USA. Electronic address:
Rheumatoid arthritis (RA) is a chronic autoimmune disorder with a complex pathogenesis that evolves through various stages before clinical symptoms emerge. This review outlines the natural history of RA, starting from genetic predisposition and environmental triggers to preclinical autoimmunity and subsequent joint inflammation. Key genetic factors interact with environmental elements like smoking and infections, producing autoantibodies such as anti-citrullinated protein antibodies (ACPA) and rheumatoid factor, which precede clinical manifestations by several years.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!